Bridging Efficacy of Tofacitinib Immediate‐Release to Extended‐Release Formulations for Treatment of Ulcerative Colitis: Application of a Model‐Informed Drug Development Approach-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Bridging Efficacy of Tofacitinib Immediate‐Release to Extended‐Release Formulations for Treatment of Ulcerative Colitis: Application of a Model‐Informed Drug Development Approach

Published:2022-05-13 Issue:8 Volume:11 Page:976-986
ISSN:2160-763X
Container-title:Clinical Pharmacology in Drug Development
language:en
Short-container-title:Clinical Pharm in Drug Dev

Author:

Mukherjee Arnab¹,Tsuchiwata Shinichi²,Chang Cheng¹,Nicholas Timothy¹,Su Chinyu³,Le Vu H.¹,Kushner Joseph¹,Kulisek Nicole³

Affiliation:

1. Pfizer Inc Groton Connecticut USA

2. Pfizer R&D Japan Tokyo Japan

3. Pfizer Inc Collegeville Pennsylvania USA

Publisher

Wiley

Subject

Pharmacology (medical),Pharmaceutical Science

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1002/cpdd.1106

Reference16 articles.

1. Tofacitinib, an Oral Janus Kinase Inhibitor, in Active Ulcerative Colitis

2. Tofacitinib as Induction and Maintenance Therapy for Ulcerative Colitis

3. DOP61 Tofacitinib, an oral, small-molecule Janus kinase inhibitor, in the treatment of ulcerative colitis: Analysis of an open-label, long-term extension study with up to 5.9 years of treatment

4. Worldwide post‐marketing safety surveillance experience with tofacitinib in ulcerative colitis

5. Dosing Frequency and Medication Adherence in Chronic Disease

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP